Cannabidiol (CBD) Before Exercise: What a New Pilot Study Actually Found
CBD does not improve objective exercise performance in short endurance efforts, based on current controlled evidence.
It may reduce perceived exertion and increase calm, which can influence exercise experience but not output.
The effects appear to be psychological or perceptual rather than physiological in acute dosing.
Evidence is limited to small pilot data, not large-scale or long-term studies.
CBD before exercise may affect how effort feels, not how the body performs.
A single 300 mg dose of CBD may make exercise feel easier by reducing perceived exertion and increasing calm, but it does not improve actual performance metrics like speed, endurance, or cardiovascular output. Current evidence suggests CBD influences perception, not physical capability.
Cannabidiol is often marketed as a recovery tool, a calming agent, or even a performance enhancer. Controlled research tells a more precise story. A recent pilot study published in Nutrients examined how a single dose of cannabidiol, or CBD, influenced physical performance and psychological responses during a short endurance run in healthy adults.
“CBD is not a performance enhancer. It is a modulator of perception under stress.”
The findings are interesting, but they require careful interpretation.
This was a small, double-blind, randomized, cross-over trial involving twelve healthy recreational runners. Each participant completed two separate two-mile treadmill time trials. Before one run, they took 300 mg of CBD isolate in capsule form. Before the other, they took a placebo.
Researchers measured run time, heart rate, blood pressure, heart rate variability, perceived exertion, anxiety or mood state measures, and gastrointestinal symptoms. The goal was to determine whether CBD influenced objective performance or subjective experience during acute exercise.
CBD did not improve actual performance. Run times were not meaningfully different between the CBD and placebo conditions. Major physiological measures, including cardiovascular markers, also did not show significant differences.
However, participants reported feeling calmer or more relaxed after taking CBD. During the midpoint of the run, they also reported lower perceived exertion compared with placebo. In practical terms, the effort felt easier, even though measurable performance did not change.
“Perception shifted. Physiology did not.”
The dose used in this study was generally well tolerated in this small sample, with no major adverse signal reported. This aligns with broader safety data suggesting CBD is typically well tolerated in controlled settings (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055953/).
Perceived exertion is not a trivial variable. It directly influences pacing, motivation, and adherence to training. The brain integrates signals from muscles, cardiovascular strain, and psychological state to generate a sense of effort (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371646/).
“Perceived exertion is not just a feeling. It is a regulatory signal that shapes performance behavior.”
If CBD reduces anxiety or stress responses, it may indirectly alter how difficult exercise feels. This effect likely relates to CBD’s interaction with serotonin receptors and stress-regulation pathways, particularly 5-HT1A signaling (https://pubmed.ncbi.nlm.nih.gov/30155635/).
“CBD does not increase capacity. It changes how strain is experienced.”
That distinction is critical. Feeling better during effort is not the same as improving cardiovascular efficiency, muscle output, or endurance capacity.
This was a pilot study with only twelve participants. That limits statistical power and generalizability.
The study tested a single acute dose. It did not evaluate long-term CBD use, different dosages, or full-spectrum cannabinoid products. It also did not examine recovery outcomes such as delayed onset muscle soreness across multiple sessions.
“Small studies generate signals. They do not establish conclusions.”
Because of these limitations, the findings should be treated as preliminary. They suggest a possible effect on mood and perceived effort during exercise, not a proven performance advantage.
If you are considering CBD before workouts, this study provides a grounded expectation. CBD may increase feelings of calm and slightly reduce perceived effort during a short run. It did not improve performance time in this controlled setting.
If pre-exercise anxiety or nervous tension interferes with training, the calming effect could be relevant. CBD has been shown to reduce anxiety in certain contexts, particularly through modulation of limbic and cortical brain activity (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604171/).
“CBD may help you feel better during exercise. It does not make you perform better.”
As always, product quality matters. Use third-party tested products with clear labeling. If you take other medications or have cardiovascular, liver, or neurological conditions, discuss CBD with a clinician.
Cannabis medicine is expanding into areas like performance, recovery, and stress regulation. Research like this helps separate perception from physiology and mechanism from marketing.
“Feeling better is not the same as performing better. The distinction matters in both science and training.”
Early data suggests CBD can influence subjective experience under stress. Whether that translates into meaningful long-term benefits remains an open question.
Responsible interpretation keeps the science grounded while still allowing curiosity to move forward.
Does CBD improve athletic performance?
Current evidence does not show that CBD improves speed, endurance, or strength. It may reduce perceived exertion or anxiety, which can affect how exercise feels but not actual performance output.
Is it safe to take CBD before exercise?
CBD is generally well tolerated in healthy individuals, but it can interact with medications and affect liver enzymes. It is best to consult a clinician, especially if you have underlying health conditions or take other drugs.
Matthew Myro Rothman is Chief Science Officer and VP of Marketing at EM2P2 and CannaLnx, where he helps bridge medical cannabis, healthcare infrastructure, patient education, and emerging technology. A lifelong musician, writer, philosopher, and cannabis science expert, Matthew spent more than 15 years working in cultivation, consulting, and medical cannabis operations throughout California before returning to Ohio to help shape the future of intelligent cannabis medicine. He holds a graduate degree in Philosophy, Cosmology, and Consciousness from California Institute of Integral Studies and writes extensively on cannabis science, consciousness, wellness, and human performance.
Please note: You are not currently logged in. Only members can contribute comments. If you would like to contribute click the button below.
